Insights from 2023 ASCO® Annual Meeting
Playback speed
10 seconds
ASCO® 2023 Insights: "FGFR3 Alterations in Phase III PROOF 302 Trial: Infigratinib (BGJ398) as Adjuvant Therapy in Patients With Invasive Urothelial Carcinoma"
By
Insights from 2023 ASCO® Annual Meeting
FEATURING
Petros Grivas
By
Insights from 2023 ASCO® Annual Meeting
FEATURING
Petros Grivas
181 views
June 6, 2023
Comments 0
Login to view comments.
Click here to Login
GU